Jim Cramer: Buy NPS Pharmaceuticals, OpenTable, and These 2 Stocks

Jim Cramer made the following calls on November 6th, 2013. What do you think about his picks?

NPS Pharmaceuticals, Inc. (NASDAQ:NPSP): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Sell on October 10, 2013. The stock’s 52-week high is $35.72, and its 52-week low is $7.35. Though many on Wall Street were not happy with NPS Pharmaceuticals for its earnings numbers, which were released yesterday, Cramer noted that the company actually beat out expectations by a small margin. However, an EPS of negative one cent, instead of the consensus estimated negative two cents, was not enough to satisfy investors, who have come to expect more from this hot stock, and the company continues to trade down by around 15 percent on the news.

Cramer talked the matter over with Francois Nader, the president and CEO of NPS, who said that Wall Street expectations were just too high this time around. Nader said that NPS still has great possibilities moving forward, including a large untapped market for their bowl syndrome drug Gattex.

npsp-20131107

OpenTable, Inc. (NASDAQ:OPEN): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on May 9, 2013. The stock’s 52-week high is $82.87, and its 52-week low is $41.68. One of the earnings winners of yesterday’s trading was OpenTable, the restaurant booking website, which delivered with EPS of 50 cents per share, a full 8 cents higher than expectations. Shares are up over 12 percent in trading, and Cramer thinks that the company has shown amazing growth and execution so far this year.

open-20131107

Pioneer Natural Resources Co. (NYSE:PXD): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on October 22, 2013. The stock’s 52-week high is $227.42, and its 52-week low is $100.48. Another stock that has dropped off due to earnings news is Pioneer Natural Resources, which Cramer says is still a fine company despite not being to live up to over-hyped investor expectations. Shares of the company are trading down over 5 percent on  what is seen as disappointing earnings news, even though the company actually performed well when compared with consensus estimates.

Cramer discussed the developments with Scott Sheffield, the chairman and CEO of Pioneer, who said that the company’s muted production growth in the quarter was nothing to be concerned with. Sheffield noted Pioneer’s presence in the Wolfcamp basin, which is on track to be one of the world’s top oil sites.

pxd-20131107

St. Jude Medical Inc. (NYSE:STJ): Jim Cramer ranked this stock a Buy. Cramer previously ranked this stock a Buy on October 18, 2013. The stock’s 52-week high is $58.99, and its 52-week low is $30.25. Cramer thought that St. Jude Medical was one of the better-executing names in its sector, earning it his seal of approval. The company was downgraded by Bernstein earlier this week after the firm expressed its belief that many of St. Jude’s near-term opportunities had already played out.

stj-20131107

Don’t Miss: 5 Ways to Fly Without Breaking the Bank.